Somaiya Mayur Ian
Chief Financial Officer at NAMS; Chief Financial Officer at TCR2 THERAPEUTICS INC.
- Sold, on record
- $3.6M
- Dollars the filings state
- Form 4 sales
- 5
- Latest Jan 21, 2026
- Form 144 notices
- 3
- Proposed sales
- Companies
- 2
- Filed as an executive or holder
Companies
- NAMSNewAmsterdam Pharma Co N.V.Chief Financial Officer
- TCR2 THERAPEUTICS INC.Chief Financial Officer
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- NAMS167,001 shares
- TCR2 THERAPEUTICS INC.5,666 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale TCR2 THERAPEUTICS INC.UnusualNov 17, 2020 2020
Sold 3,666 shares at $30.00 ($110k)
Somaiya Mayur Ian, Chief Financial Officer
Sold 71.3% of holdings ($154k position)1,473 shares leftFirst sale on recordFiling
- 2 Form 4 sale TCR2 THERAPEUTICS INC.UnusualDec 14, 2020 +27 days
Sold 2,000 shares at $35.00 ($70k)
Somaiya Mayur Ian, Chief Financial Officer
Sold 57.6% of holdings ($122k position)1,473 shares leftFiling
- 3 Form 144 notice NAMSNoticeJan 27, 2025 +1505 days
Filed to sell 200,000 shares ($4.6M)
Somaiya Mayur Ian, Affiliate
10b5-1 planFirst sale on recordFiling
- 4 Form 4 sale NAMSRoutineJan 28, 2025 +1 day
Sold 61,883 shares
Somaiya Mayur Ian, Chief Financial Officer
10b5-1 planSold 62% of holdings38,000 shares leftFirst sale on recordFollows a Form 144Filing
- 5 Form 144 notice NAMSNoticeJan 5, 2026 +342 days
Filed to sell 5,118 shares ($170k)
Somaiya Mayur Ian, affiliate
No 10b5-1 planFiling
- 6 Form 4 sale NAMSRoutineJan 5, 2026 same day
Sold 5,118 shares at $33.25 ($170k)
Somaiya Mayur Ian, Chief Financial Officer
10b5-1 planSold 13.5% of holdings ($1.3M position)32,882 shares leftFollows a Form 144Filing
- 7 Form 144 notice NAMSNoticeJan 20, 2026 +15 days
Filed to sell 200,000 shares ($6.3M)
Somaiya Mayur Ian, Affiliate
10b5-1 planFiling
- 8 Form 4 sale NAMSRoutineJan 21, 2026 +1 day
Sold 100,000 shares at $32.61 ($3.3M)
Somaiya Mayur Ian, Chief Financial Officer
10b5-1 planSold 63.1% of holdings ($5.2M position)58,382 shares leftFollows a Form 144Filing
Every transaction
Loading transactions…
Sales and notices (8)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Jan 21, 2026 | Jan 22, 2026 | NAMS | Chief Financial Officer | Form 4 sale | 100,000 | $3.3M | 63.1% | Routine | SEC |
| Jan 20, 2026 | Jan 20, 2026 | NAMS | Affiliate | Form 144 notice | 200,000 | $6.3M | Notice | SEC | |
| Jan 5, 2026 | Jan 7, 2026 | NAMS | Chief Financial Officer | Form 4 sale | 5,118 | $170k | 13.5% | Routine | SEC |
| Jan 5, 2026 | Jan 5, 2026 | NAMS | affiliate | Form 144 notice | 5,118 | $170k | Notice | SEC | |
| Jan 28, 2025 | Jan 29, 2025 | NAMS | Chief Financial Officer | Form 4 sale | 61,883 | 62.0% | Routine | SEC | |
| Jan 27, 2025 | Jan 27, 2025 | NAMS | Affiliate | Form 144 notice | 200,000 | $4.6M | Notice | SEC | |
| Dec 14, 2020 | Dec 16, 2020 | TCR2 THERAPEUTICS INC. | Chief Financial Officer | Form 4 sale | 2,000 | $70k | 57.6% | Unusual | SEC |
| Nov 17, 2020 | Nov 19, 2020 | TCR2 THERAPEUTICS INC. | Chief Financial Officer | Form 4 sale | 3,666 | $110k | 71.3% | Unusual | SEC |